Back to Search
Start Over
BCL2 Inhibition by Venetoclax: Targeting the Achilles' Heel of the Acute Myeloid Leukemia Stem Cell?
- Source :
-
Cancer discovery [Cancer Discov] 2016 Oct; Vol. 6 (10), pp. 1082-1083. - Publication Year :
- 2016
-
Abstract
- Venetoclax is an oral drug with an excellent side-effect profile that has the potential to revolutionize acute myeloid leukemia (AML) therapy in two areas. Venetoclax-based combination therapies could be a bridge to hematopoietic cell transplant with curative intent for patients with refractory/relapsed AML, and venetoclax-based therapy could provide meaningful survival prolongation for older patients with AML who are not candidates for more aggressive therapies. Cancer Discov; 6(10); 1082-3. ©2016 AACR.See related article by Konopleva and colleagues, p. 1106.<br /> (©2016 American Association for Cancer Research.)
Details
- Language :
- English
- ISSN :
- 2159-8290
- Volume :
- 6
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Cancer discovery
- Publication Type :
- Academic Journal
- Accession number :
- 27698099
- Full Text :
- https://doi.org/10.1158/2159-8290.CD-16-0921